20 articles
Pfizer's landmark trial examines whether tafamidis can safely treat transthyretin amyloid cardiomyopathy, a progressive and often fatal heart condition.
Natural isoflavone prevents cardiac enlargement through novel mitochondrial protection pathway, offering new therapeutic approach.
A Phase 1/2 trial tests whether nicotinamide riboside can restore NAD+ balance and improve heart function in systolic HF patients.
Review reveals how NAD+ precursors like NMN could restore heart function by fixing cellular energy production and reducing oxidative damage.
A 330-patient multicenter RCT tests whether thymosin ฮฑ1 can curb immune dysregulation and organ dysfunction after acute type A aortic dissection repair.
New research shows citrate supplementation restores blood vessel function and extends lifespan by improving mitochondrial health.
Breakthrough treatment works through multiple mechanisms beyond the lungs, enhancing oxygen delivery and muscle function.
A comprehensive GeneReviews update on Barth syndrome outlines diagnosis, new targeted therapy, and surveillance strategies for this rare X-linked disorder.
Sotatercept emerges as potential treatment for combined pre-capillary pulmonary hypertension and heart failure with preserved ejection fraction.
A comprehensive review reveals tirzepatide improves blood pressure, lipids, liver fat, kidney function, and slashes 10-year cardiovascular risk by up to 23.5%.
High-dose nicotinamide riboside increased atherosclerotic plaques and inflammation in mice, challenging NAD+ supplement safety.
Sotatercept reduced dangerous pressure in heart failure patients' lungs and improved walking ability in phase 2 study.
Breakthrough anti-fibril depleters could revolutionize treatment for transthyretin amyloid cardiomyopathy, a deadly heart condition.
New research shows inhibiting fatty acid synthase prevents cardiac hypertrophy and restores heart function in multiple models.
New rabbit study reveals how exercise strengthens vulnerable plaques that cause heart attacks by restoring protective cellular signaling.
Isoquercitrin reshapes gut bacteria and tryptophan metabolism to reduce arterial plaque, pointing to a novel gut-heart therapeutic pathway.
Small trial explores how amiloride improves oxygen delivery to heart muscle by enhancing potassium transport in red blood cells.
Researchers outline promising therapies for Takayasu arteritis that could reduce cardiovascular complications in young women.
Major study shows tirzepatide reduces cardiovascular and kidney complications by 16% compared to dulaglutide in diabetic patients.
Major analysis of 38,089 older adults shows aggressive lipid-lowering therapy significantly reduces cardiovascular events.
